Navigation Links
Halozyme Reports Second Quarter 2013 Financial Results
Date:8/7/2013

SAN DIEGO, Aug. 7, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter and six months ended June 30, 2013. Financial highlights for the second quarter include revenues of $14.5 million and a net loss of $22.9 million or $0.20 per share. This compares to revenues of $7.8 million and a net loss of $14.0 million or $0.13 per share for the second quarter of 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"Significant regulatory milestones were achieved with Baxter's HyQvia and Roche's Herceptin last quarter. Working with our partners, we look forward to bringing these life-changing treatments to patients and medical communities across Europe," said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme. "We also announced clinical advancement of our proprietary programs in pancreatic cancer, diabetes and dermatology, further accelerating our key value drivers enabled by our technology platform."

Second Quarter and Recent Business Updates

  • EU Regulatory Progress for Herceptin SC and HyQvia: The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion to Roche for the use of a subcutaneous formulation of Herceptin (trastuzumab) as treatment for patients with HER2-positive breast cancer. In addition, the European Commission granted Baxter marketing authorization in all European Union member states for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Baxter launched HyQvia into the first EU country in July and plans to introduce the product into additional EU countries over the coming quarters. The first commercial sale of HyQvia in
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
    2. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
    3. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
    4. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
    5. Halozyme Reports First Quarter 2013 Financial Results
    6. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
    7. Halozyme Therapeutics Names Matt Posard to Board of Directors
    8. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
    9. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
    10. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
    11. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/2/2014)... , Oct. 2, 2014  Isis Pharmaceuticals, Inc. ... webcast:What: , Webcast and conference call to provide ... clinical studies of ISIS-SMN Rx in infants ... will be presented on the morning (CEST) of ... Muscle Society in Berlin, GermanyWhen:Friday, October 10 at ...
    (Date:10/2/2014)... Ireland , Oct. 2, 2014   West ... a global leader in innovative solutions for injectable drug ... manufacturing operations to include a new site in ... produce packaging components for insulin injector cartridges and other ... from pharmaceutical and biotech customers. Once operational, this new ...
    (Date:10/2/2014)... 2014   Intarcia Therapeutics, Inc. today announced ... 3 clinical trials for ITCA 650 (exenatide, delivered continuously ... mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, double-blind ... safety of ITCA 650 in patients with type 2 ... be significantly superior to placebo for both 40 mcg ...
    Breaking Medicine Technology:Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
    ... , BOSTON, Nov. 17 ... and information management solutions, today announced that it will showcase ... (IDNs) at the 2009 Radiological Society of North America (RSNA) ... IL. AMICAS will be in the North Hall in booth ...
    ... HistoRx today announced that the Company,s proprietary AQUA technology, ... was noted in a recent National Comprehensive Cancer ... testing in breast cancer as one of the "... promising ... PgR in breast cancer tissue." Experts from the country,s ...
    Cached Medicine Technology:AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 2AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 3AQUA(R) Technology Recognized as 'Promising New Strategy' for Hormone Receptor Testing in Breast Cancer by NCCN Task Force 2
    (Date:10/2/2014)... have pinpointed a molecule that may trigger potentially life-threatening ... say this finding could offer a target for new ... Most asthma attacks (80 percent to 90 percent) are ... the British researchers. Most of these are rhinoviruses, which ... The researchers found that a specific molecule called IL-25 ...
    (Date:10/2/2014)... Norton HealthDay Reporter WEDNESDAY, Oct. ... the roses -- literally -- may face an increased risk of ... a study of over 3,000 older Americans, researchers found those who ... were more than three times as likely to die in the ... In fact, anosmia -- the inability to distinguish odors -- ...
    (Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
    (Date:10/1/2014)... 1, 2014 Patients with increased inflammation, including ... greatly increased risk of depression. For example, a ... hepatitis C virus infection causes depression in approximately ... more commonly known as fish oil, have a ... risk of heart disease and reducing triglyceride levels. ...
    (Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
    Breaking Medicine News(10 mins):Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2
    ... poses heightened risk, but it,s talked about by only ... -- Even though people with rheumatoid arthritis (RA) may ... rarely discussed with their doctors, says a U.S. study ... , The researchers, led by Betsy Sleath, of the ...
    ... of Preventive Medicine and Partnership for Prevention ... Killer -, WASHINGTON, Feb. 11 The ... Prevention (Partnership) have joined,forces to change the way ... cost-effective disease prevention. The organizations,have targeted heart disease, ...
    ... PRINCETON, N.J., Feb. 11 New Jersey,s,hospitals would lose ... total,of $2.9 billion through 2013 if President Bush,s proposed ... by the New Jersey,Hospital Association., The cuts are ... last week. All told, the budget plan calls for ...
    ... HealthPartners first Minnesota health care organization to measure ... BLOOMINGTON, Minn., Feb. 11 HealthPartners,today released a ... different racial/ethnic backgrounds receiving certain types of,care in ... exist and,examples of improvements it is making to ...
    ... Women,s Cancer, Theme, Spotlights Four Decades of ... CHICAGO, Feb. 11 The Society of Gynecologic,Oncologists ... Women,s Cancer March,9-12 at the Tampa Convention Center ... more than 350 scientific presentations,lectures, workshops, symposium, surgical ...
    ... of UPMC have identified a key protein target that may ... to prevent and new therapies to treat pneumonia, the leading ... Kolls, MD, chief of the Division of Pediatric Pulmonary Medicine, ... the importance of a protein known as interleukin 22 (IL-22) ...
    Cached Medicine News:Health News:Depression Rarely Discussed With RA Patients 2Health News:Nation's Leading Preventive Health Groups Seek to Save Lives by Transforming Americans' Approach to Health 2Health News:Nation's Leading Preventive Health Groups Seek to Save Lives by Transforming Americans' Approach to Health 3Health News:Nation's Leading Preventive Health Groups Seek to Save Lives by Transforming Americans' Approach to Health 4Health News:Bush Budget Cuts Total $2.9 Billion for N.J. Hospitals 2Health News:New Report Identifies Health Disparities and Reduction Strategies 2Health News:Society of Gynecologic Oncologists to Host 39th Annual Meeting on Women's Cancer 2Health News:Society of Gynecologic Oncologists to Host 39th Annual Meeting on Women's Cancer 3Health News:Children's Hospital scientists identify possible target for prevention and treatment of pneumonia 2
    Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
    Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
    Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
    Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
    Medicine Products: